Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced that it has received fast-track designation from the US Food and Drug Administration (FDA) for its antibody drug conjugate (ADC) 9MW2821. This candidate targets Nectin-4 and is under investigation for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).
Once administered, 9MW2821 is designed to bind with Nectin-4 present on the surface of tumor cells, internalizing into the cells. Through enzymatic hydrolysis, it releases cytotoxic agents in a targeted manner, aiming to achieve precise tumor cell destruction.- Flcube.com
